Tessa Cigler

2.0k total citations
54 papers, 1.2k citations indexed

About

Tessa Cigler is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Tessa Cigler has authored 54 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 15 papers in Cancer Research. Recurrent topics in Tessa Cigler's work include Cancer Treatment and Pharmacology (10 papers), HER2/EGFR in Cancer Research (7 papers) and PARP inhibition in cancer therapy (6 papers). Tessa Cigler is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), HER2/EGFR in Cancer Research (7 papers) and PARP inhibition in cancer therapy (6 papers). Tessa Cigler collaborates with scholars based in United States, United Kingdom and Canada. Tessa Cigler's co-authors include Linda T. Vahdat, Anne Moore, Ellen Chuang, Michelle Melisko, Maureen M. Ward, Maureen E. Lane, Peter A. Torzilli, Diana Donovan, C. Theresa Vincent and Shari Goldfarb and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Tessa Cigler

52 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tessa Cigler United States	20	633	261	189	176	171	54	1.2k
Florence Joly France	15	483 0.8×	243 0.9×	81 0.4×	199 1.1×	73 0.4×	56	1.4k
Daniel Lee United States	18	157 0.2×	523 2.0×	140 0.7×	321 1.8×	109 0.6×	62	1.5k
Dimosthenis Chrysikos Greece	18	457 0.7×	253 1.0×	195 1.0×	254 1.4×	85 0.5×	119	1.2k
Sara López‐Tarruella Spain	19	672 1.1×	228 0.9×	277 1.5×	240 1.4×	95 0.6×	89	962
Akiyo Yoshimura Japan	18	508 0.8×	377 1.4×	352 1.9×	279 1.6×	66 0.4×	67	1.2k
Laura Zanotti Italy	27	527 0.8×	546 2.1×	352 1.9×	341 1.9×	115 0.7×	76	1.9k
Christine M. Kearns United States	15	884 1.4×	223 0.9×	74 0.4×	237 1.3×	64 0.4×	22	1.3k
Μakoto Fujime Japan	18	284 0.4×	678 2.6×	145 0.8×	314 1.8×	55 0.3×	73	1.3k
James P. LaPolla United States	18	453 0.7×	486 1.9×	185 1.0×	100 0.6×	368 2.2×	33	1.7k
Erwin A. Kruger United States	20	323 0.5×	748 2.9×	360 1.9×	313 1.8×	59 0.3×	45	1.6k

Countries citing papers authored by Tessa Cigler

Since Specialization

Citations

This map shows the geographic impact of Tessa Cigler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tessa Cigler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tessa Cigler more than expected).

Fields of papers citing papers by Tessa Cigler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tessa Cigler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tessa Cigler. The network helps show where Tessa Cigler may publish in the future.

Co-authorship network of co-authors of Tessa Cigler

This figure shows the co-authorship network connecting the top 25 collaborators of Tessa Cigler. A scholar is included among the top collaborators of Tessa Cigler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tessa Cigler. Tessa Cigler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ivanidze, Jana, Andrew Brandmaier, Eleni Andreopoulou, et al.. (2024). [18F]-Fluoroestradiol (FES) brain PET in the evaluation of patients with estrogen receptor positive breast cancer and known or suspected brain metastases. European Journal of Radiology. 181. 111791–111791. 1 indexed citations

Nicolò, Eleonora, Lisa A. Newman, Tessa Cigler, et al.. (2023). Impact of HER2 low expression in the Oncotype DX RS in patients with operable hormone receptor positive early stage breast cancer.. Journal of Clinical Oncology. 41(16_suppl). 575–575. 1 indexed citations

Lee, Shing Yip, Amy Tiersten, Della Makower, et al.. (2021). Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer. Breast Cancer Research and Treatment. 189(1). 177–185. 22 indexed citations

Oktay, Kutluk, Giuliano Bedoschi, Shari Goldfarb, et al.. (2020). Increased chemotherapy-induced ovarian reserve loss in women with germline BRCA mutations due to oocyte deoxyribonucleic acid double strand break repair deficiency. Fertility and Sterility. 113(6). 1251–1260.e1. 47 indexed citations

Goldfarb, Shari, Volkan Turan, Giuliano Bedoschi, et al.. (2020). Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer. Breast Cancer Research and Treatment. 185(1). 165–173. 28 indexed citations

Oktay, Kutluk, Giuliano Bedoschi, Enes Taylan, et al.. (2019). Abstract PD6-06: Impact of BRCA mutations on chemotherapy-induced loss of ovarian reserve: A prospective longitudinal study. Cancer Research. 79(4_Supplement). PD6–6. 1 indexed citations

Elkin, Elena B., et al.. (2017). Facilitating informed decisions about breast cancer screening: development and evaluation of a web-based decision aid for women in their 40s. BMC Medical Informatics and Decision Making. 17(1). 29–29. 25 indexed citations

Nackos, Eleni, Sharrell Lee, Amy D. Willis, et al.. (2016). Abstract LB-349: Copper depletion as a strategy to affect the tumor microenvironment in breast cancer patients at high risk of relapse and in triple negative preclinical models of breast cancer: Updated results of a phase II study of tetrathiomolybdate (TM) in breast cancer (BC) patients (pts) at high risk for recurrence. Cancer Research. 76(14_Supplement). LB–349. 1 indexed citations

Yardley, Denise A., Robert Weaver, Michelle Melisko, et al.. (2015). EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast Cancer. Journal of Clinical Oncology. 33(14). 1609–1619. 145 indexed citations

10.

Somlo, George, Paul Frankel, Thehang Luu, et al.. (2015). Efficacy of the PARP inhibitor (PI) ABT-888 (veliparib [vel]) either with carboplatin (carb) or as a single agent followed by post-progression therapy in combination with carb in patients (pts) with BRCA1- or BRCA2- (BRCA)-associated metastatic breast cancer (MBC).. Journal of Clinical Oncology. 33(15_suppl). 520–520. 8 indexed citations

11.

Stanton, Sasha E., Maureen M. Ward, Paul J. Christos, et al.. (2015). Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity. BMC Cancer. 15(1). 267–267. 56 indexed citations

12.

Cigler, Tessa, et al.. (2014). Hypovitaminosis D is a Predictor of Aromatase Inhibitor Musculoskeletal Symptoms. The Breast Journal. 20(2). 174–179. 16 indexed citations

13.

Torzilli, Peter A., et al.. (2012). A new paradigm for mechanobiological mechanisms in tumor metastasis. Seminars in Cancer Biology. 22(5-6). 385–395. 49 indexed citations

14.

Andreopoulou, Eleni, Jo Anne Zujewski, Kevin Kalinsky, et al.. (2011). Randomized, double-blind, placebo-controlled phase II trial of low-dose metronomic cyclophosphamide alone or in combination with veliparib (ABT-888) in chemotherapy-resistant ER and/or PR-positive, HER2/neu-negative metastatic breast cancer: New York Cancer Consortium trial P8853.. Journal of Clinical Oncology. 29(15_suppl). TPS114–TPS114. 2 indexed citations

15.

Cigler, Tessa, Harriet Richardson, Martin J. Yaffe, et al.. (2011). A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women. Breast Cancer Research and Treatment. 126(2). 453–461. 34 indexed citations

16.

Cigler, Tessa & Linda T. Vahdat. (2010). Eribulin mesylate for the treatment of breast cancer. Expert Opinion on Pharmacotherapy. 11(9). 1587–1593. 18 indexed citations

17.

Cigler, Tessa, Dongsheng Tu, Martin J. Yaffe, et al.. (2009). A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women. Breast Cancer Research and Treatment. 120(2). 427–435. 30 indexed citations

18.

Cigler, Tessa & Linda T. Vahdat. (2008). Integrating Epothilones into the Treatment of Patients with Metastatic Breast Cancer: Clinical Perspectives on Incorporating Recent Data in the Practice Setting. Clinical Breast Cancer. 8. S166–S170. 3 indexed citations

19.

Cigler, Tessa & Paul E. Goss. (2007). Breast Cancer Adjuvant Endocrine Therapy. The Cancer Journal. 13(3). 148–155. 13 indexed citations

20.

Cigler, Tessa, et al.. (2001). Novel and previously reported single‐nucleotide polymorphisms in the human 5‐HT_1B receptor gene: No association with cocaine or alcohol abuse or dependence. American Journal of Medical Genetics. 105(6). 489–497. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact